PIV3 | Clinical Trials Search

81 results for “PIV3”

Need more precision?

Filter by phase, recruitment status, country, sponsor, age, and study type.

Refine trial search

Active, not recruiting

Study of an RSV-hMPV-PIV3 Trivalent Vaccine Candidate VXB-251 in Older Adults

240 participants · First posted Dec 19, 2025

Active, not recruiting

Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older

390 participants · First posted Sep 19, 2024

Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children

120 participants · First posted Jun 28, 2006

Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

51 participants · First posted Oct 30, 2019

A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.

270 participants · First posted Feb 27, 2025

A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants

1,338 participants · First posted May 29, 2008

A Phase 1/2A Study to Evaluate the Safety, Immunogenicity, and Shedding of MEDI-560 in Infants 1 to < 12 Months of Age

30 participants · First posted Jul 30, 2007

Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children

28 participants · First posted Dec 6, 2010

Safety of and Immune Response to a Cow/Human Parainfluenza Virus Vaccine (rB/HPIV3) in Healthy Infants, Children, and Adults

51 participants · First posted Aug 21, 2006

Active, not recruiting

Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults

612 participants · First posted May 22, 2025

Page 1 of 6